KRAS and neoplasm: To validate in vitro antitumor activity of TCR-engineered T cells, most investigators usually use tumor cell lines that express KRAS mutations and the appropriate HLA, either endogenously expressed or genetically overexpressed (1, 6–8, 12–15).